Literature DB >> 27919008

Phenotype analysis of male transgenic mice overexpressing mutant IGFBP-2 lacking the Cardin-Weintraub sequence motif: Reduced expression of synaptic markers and myelin basic protein in the brain and a lower degree of anxiety-like behaviour.

N Schindler1, J Mayer2, S Saenger3, U Gimsa4, C Walz1, J Brenmoehl1, D Ohde1, E Wirthgen1, A Tuchscherer5, V C Russo6, M Frank7, T Kirschstein2, F Metzger3, A Hoeflich8.   

Abstract

Brain growth and function are regulated by insulin-like growth factors I and II (IGF-I and IGF-II) but also by IGF-binding proteins (IGFBPs), including IGFBP-2. In addition to modulating IGF activities, IGFBP-2 interacts with a number of components of the extracellular matrix and cell membrane via a Cardin-Weintraub sequence or heparin binding domain (HBD1). The nature and the signalling elicited by these interactions are not fully understood. Here, we examined transgenic mice (H1d-hBP2) overexpressing a mutant human IGFBP-2 that lacks a specific heparin binding domain (HBD1) known as the Cardin-Weintraub sequence. H1d-hBP2 transgenic mice have the genetic background of FVB mice and are characterized by severe deficits in brain growth throughout their lifetime (p<0.05). In tissue lysates from brain hemispheres of 12-21day old male mice, protein levels of the GTPase dynamin-I were significantly reduced (p<0.01). Weight reductions were also found in distinct brain regions in two different age groups (12 and 80weeks). In the younger group, impaired weights were observed in the hippocampus (-34%; p<0.001), cerebellum (-25%; p<0.0001), olfactory bulb (-31%; p<0.05) and prefrontal cortex (-29%; p<0.05). At an age of 12weeks expression of myelin basic protein was reduced (p<0.01) in H1d-BP-2 mice in the cerebellum but not in the hippocampus. At 80weeks of age, weight reductions were similarly present in the cerebellum (-28%; p<0.001) and hippocampus (-31; p<0.05). When mice were challenged in the elevated plus maze, aged but not younger H1d-hBP2 mice displayed significantly less anxiety-like behaviour, which was also observed in a second transgenic mouse model overexpressing mouse IGFBP-2 lacking HBD1 (H1d-mBP2). These in vivo studies provide, for the first time, evidence for a specific role of IGFBP-2 in brain functions associated with anxiety and risk behaviour. These activities of IGFBP-2 could be mediated by the Cardin-Weintraub/HBD1 sequence and are altered in mice expressing IGFBP-2 lacking the HBD1.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Elevated plus maze; Heparin binding domain; IGFBP-2; Mouse brain; Myelin; Synaptic marker

Mesh:

Substances:

Year:  2016        PMID: 27919008     DOI: 10.1016/j.ghir.2016.11.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  4 in total

1.  Peripheral versus Central Index of Metabolic Dysfunction and Associations with Clinical and Pathological Outcomes in Alzheimer's Disease.

Authors:  Kelsey E McLimans; Joseph L Webb; Vellareddy Anantharam; Anumantha Kanthasamy; Auriel A Willette
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Under or Absent Reporting of Light Stimuli in Testing of Anxiety-Like Behaviors in Rodents: The Need for Standardization.

Authors:  Lorenz S Neuwirth; Michael T Verrengia; Zachary I Harikinish-Murrary; Jessica E Orens; Oscar E Lopez
Journal:  Front Mol Neurosci       Date:  2022-08-17       Impact factor: 6.261

3.  Circulating IGFBP-2: a novel biomarker for incident dementia.

Authors:  Emer R McGrath; Jayandra J Himali; Daniel Levy; Sarah C Conner; Charles S DeCarli; Matthew P Pase; Paul Courchesne; Claudia L Satizabal; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri
Journal:  Ann Clin Transl Neurol       Date:  2019-08-02       Impact factor: 4.511

Review 4.  Meninges: A Widespread Niche of Neural Progenitors for the Brain.

Authors:  Ilaria Decimo; Sissi Dolci; Gabriella Panuccio; Marco Riva; Guido Fumagalli; Francesco Bifari
Journal:  Neuroscientist       Date:  2020-09-16       Impact factor: 7.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.